These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28167540)

  • 1. Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.
    Mahmood M; Abu Saleh O; Sohail MR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167540
    [No Abstract]   [Full Text] [Related]  

  • 2. Posaconazole-Induced Pseudohyperaldosteronism.
    Kuriakose K; Nesbitt WJ; Greene M; Harris B
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530850
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Thompson GR; Chang D; Wittenberg RR; McHardy I; Semrad A
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suspected posaconazole toxicity in a pediatric oncology patient.
    Martino J; Fisher BT; Bosse KR; Bagatell R
    Pediatr Blood Cancer; 2015 Sep; 62(9):1682. PubMed ID: 25950873
    [No Abstract]   [Full Text] [Related]  

  • 5. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
    Clark NM; Grim SA; Lynch JP
    Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
    Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
    J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.
    Parkes LO; Cheng MP; Sheppard DC
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1170-1. PubMed ID: 26643343
    [No Abstract]   [Full Text] [Related]  

  • 8. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation.
    Hoffmann WJ; McHardy I; Thompson GR
    Mycoses; 2018 May; 61(5):337-339. PubMed ID: 29385285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage treatment of histoplasmosis with posaconazole.
    Restrepo A; Tobón A; Clark B; Graham DR; Corcoran G; Bradsher RW; Goldman M; Pankey G; Moore T; Negroni R; Graybill JR
    J Infect; 2007 Apr; 54(4):319-27. PubMed ID: 16824608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole prophylaxis in hematologic cancer.
    Krause DS
    N Engl J Med; 2007 May; 356(21):2215; author reply 2215-8. PubMed ID: 17526091
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypokalaemia in patients with acute myeloid leukaemia after treatment with fluconazole.
    Kidd D; Ranaghan EA; Morris TC
    Lancet; 1989 May; 1(8645):1017. PubMed ID: 2565490
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
    Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole (Noxafil) for invasive fungal infections.
    Med Lett Drugs Ther; 2006 Nov; 48(1248):93-5. PubMed ID: 17106434
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The latest data on posaconazole].
    Paugam A
    Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.